These findings published by the Bergmeier lab in the Journal of Clinical Investigation could lead to more personalized approaches to controlling platelet activity during heart attacks and other vascular emergencies and diseases.
Brian Strahl along with other scientists at UNC have created a new way to investigate epigenetic mechanisms important in diseases ranging from Alzheimer’s to cancers. Read more about their work published in Developmental Cell.
By deleting the NrCAM gene, scientists have found a potential way to cut back on the neural connections implicated in Autism Spectrum Disorder.
Sixteen years after scientists found the genes that control the circadian clock in all cells, the lab of UNC’s Aziz Sancar, MD, PhD, discovered the mechanisms responsible for keeping the clock in sync.
Congratulations to the Strahl Lab for their recent article "Catalysis-dependent stabilization of Bre1 fine-tunes Histone H2B ubiquitylation to regulation gene transcription" that was published in the August 1, 2014 issue of Genes and Development.
Congratulations to the Swanstrom lab that published an article titled "A fitness bottleneck in HIV-1 transmission" in the July 11, 2014 issue of Science.
For more than 20 years, Sharon Campbell, PhD, has been studying Ras, a protein implicated in 30 percent of all cancers. Now she’s on the hunt for alternative ways to shut the protein down.
Michael Miley, PhD and Ashutosh Tripathy, PhD announced as the new co-directors for the UNC Center for Structural Biology (CSB). CSB has also launched a brand new website.
Congratulations to Dr. Sharon Campbell, Professor of Biochemistry & Biophysics, who is the recipient of the 2014 Hyman L. Battle Distinguished Cancer Research Award.
Dr. Aziz Sancar enjoying the games last week with several others.
We welcome Dr. Silvia Ramos who has just joined the lab of Dr. Bill Marzluff as a new research faculty member in the Department.
Drs. Brian Strahl, Professor of Biochemistry and Biophysics at UNC-Chapel Hill along with Or Gozani, Associate Professor at Stanford, and Mark Bedford, Professor of Molecular Carcinogenesis at the University of Texas are the scientific founders of EpiCypher, a company that develops and manufactures novel products and tools for epigenetics and chromatin biology research. As of earlier this month, the operations have been moved from Texas to UNC-Chapel Hill campus.